Specialized Cancer Center Support Grant

专门癌症中心支持补助金

• 批准号: 7667622
• 负责人: DENNIS CARSON
• 金额: $ 11.59万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-07-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7667622
• 关键词: Address; Aging; Antineoplastic Agents; Appointment; Attitude; Award; Basic Science; Biological Sciences; Biotechnology; California; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cladribine; Clinical; Clinical Research; Clinical Trials; Community Services; Complement; Comprehensive Cancer Center; Contracts; Development; Diagnosis; Diagnostic; Direct Costs; Division of Cancer Prevention; Doctor of Philosophy; Education and Outreach; Educational process of instructing; Environment; Faculty; Funding; Genomics; Goals; Grant; Grant Review; Hairy Cell Leukemia; Hematologic Neoplasms; Immunologist; Industry; Institutes; International; Laboratories; Lead; Leadership; Legal patent; Life; Location; Malignant Neoplasms; Medicine; NCI Center for Cancer Research; NCI-Designated Cancer Center; Neoplasm Metastasis; New Agents; Patient Care; Patients; Peer Review; Pharmaceutical Preparations; Physicians; Prevention; Private Sector; Productivity; Publications; Rate; Recommendation; Recording of previous events; Reporting; Research; Research Activity; Research Institute; Research Personnel; Resource Sharing; Role; Scientist; Site; Source; Structure; Symptoms; System; Technology; Testing; Therapeutic Clinical Trial; Time; Translational Research; Translations; Underserved Population; United States National Academy of Sciences; Universities; Vision; anticancer research; bench to bedside; cancer genetics; cancer health disparity; cancer prevention; cancer site; cancer therapy; design; drug development; experience; instrumentation; interdisciplinary collaboration; medical schools; member; novel therapeutics; physical science; prevent; professor; programs; success; tumor growth

The Moores Cancer Center [MCC] at the University of California, San Diego [UCSD] is a matrix cancer center with 225 members from 18 university departments. Peer-reviewed funding for UCSD investigators is $102 million (direct cost), of which $32 million originates from the NCI. An additional $13.8 million from nonpeer reviewed sources results in total direct cost funding of $115.8 Million. A new 270,000 sq ft multipurpose Cancer Center building opened in April, 2005. It is located on the UCSD campus, surrounded by several other major life science research institutes and 470 biotechnology companies in La Jolla, which is commonly referred to as the "Golden Triangle" of biotechnology. The MCC is the only NCI designated comprehensive cancer center in this prolific cancer research region. Given this advantage, the long term vision for the Moores Cancer Center is to become the major hub in Southern California for the discovery and testing of new agents for the prevention, diagnosis and treatment of cancer. The new MCC building was specifically designed to: (1) stimulate interdisciplinary collaboration between physicians and scientists in the Center's Divisions of Cancer Prevention and Control, Basic Science, and Clinical and Translational Research; (2) assemble in a common and accessible site the extensive NCIsupported Shared Resources, and (3) act as a central gathering site for cancer translational researchers within the public and private sectors of Southern California. Since the building's opening only one year ago, patient accrual to therapeutic clinical trials has more than doubled. This application reports on 11 Shared Resources and seven Research Programs which reflect the scientific strengths and goals of the MCC. Four programs are existing - Cancer Biology, Cancer Genetics, Cancer Prevention and Control, Cancer Symptom Control, and three are new- Hematologic Malignancies, Reducing Cancer Disparities, and Tumor Growth, Invasion and Metastasis. This application also summarizes our plans for the deployment of new therapeutics originating from research occurring in MCC laboratories and collaborating institutes. The leadership of the MCC, supported by the UCSD administration, places the highest priority on research discovery and its translation into meaningful advances to prevent, ameliorate and eliminate the burden of cancer.

位于圣地亚哥加州大学[UCSD]的Moores癌症中心[MCC]是一个基质癌 该中心拥有来自18个大学部门的225名成员。对UCSD调查人员的同行审查资金是 1.02亿美元（直接费用），其中3 200万美元来自国家癌症研究所。来自非同行的额外1380万美元 经审查，直接费用供资总额为1.158亿美元。一个新的270，000平方英尺的多功能 癌症中心大楼于2005年4月开放。它位于UCSD校园内，周围环绕着 其他几个主要的生命科学研究机构和470家生物技术公司在拉霍亚，这是 通常被称为生物技术的“金三角”。MCC是唯一指定的NCI 在这个多产的癌症研究地区建立了一个综合癌症中心。鉴于这一优势，长期 摩尔癌症中心的愿景是成为南加州的主要枢纽， 发现和测试用于预防、诊断和治疗癌症的新药。 MCC新大楼的设计目的是：（1）促进跨学科合作， 该中心癌症预防和控制、基础科学和 临床和转化研究;（2）在一个共同的和可访问的网站上收集广泛的NCI支持的 共享资源，（3）作为癌症转化研究人员的中心聚集地 在南加州的公共和私营部门。自该建筑开业仅一年以来， 参加治疗性临床试验的患者增加了一倍多。此应用程序报告11共享 资源和七个研究计划，反映了MCC的科学优势和目标。四 癌症生物学、癌症遗传学、癌症预防和控制、癌症症状 对照，三个是新的-血液系统恶性肿瘤，减少癌症差异，和肿瘤生长， 侵袭和转移。 本申请还总结了我们的计划，部署新的疗法源于研究 发生在MCC实验室和合作研究所。管理协委会的领导层得到了 加州大学圣地亚哥分校的管理，地方的最高优先级研究发现和转化为有意义的 预防、改善和消除癌症负担的进展。